27 results about "Combination drug" patented technology

The application provides a combination drug of a PLA2G7 inhibitor and a chemotherapeutic drug and its use in resisting triple-negative breast cancer, and belongs to the technical field of medicines. The combination drug is a PLA2G7 inhibitor and a chemotherapeutic drug in the same or different specifications of unit preparations for simultaneous or separate administration, and a pharmaceutically acceptable carrier. The application first discovers and proves that the PLA2G7 inhibitor Darapladib can significantly enhance the anti-tumor activity of paclitaxel, 5-fluorouracil or cisplatin on triple-negative breast cancer, and meanwhile, the combination of the PLA2G7 inhibitor and paclitaxel has a synergistic effect in down-regulating the phosphorylation level of STAT3 protein in cancer cells and inhibiting the growth and proliferation of cancer cells; the combination of the PLA2G7 inhibitor and 5-fluorouracil also shows a synergistic effect in inhibiting the growth and proliferation of cancer cells. The application provides a new and effective combination drug strategy for improving the treatment effect of the chemotherapeutic drug on triple-negative breast cancer.

This invention discloses a trimethyl chitosan-hyaluronic acid-FMNL2 siRNA nanomedicine and its applications. The siRNA molecule consists of a sense strand and an antisense strand, which are anti-complementary to form a double-stranded RNA structure. Each of the sense and antisense strands independently contains two pendant deoxythymidines at its 3' end. The nanomedicine uses trimethyl chitosan as its core framework, efficiently encapsulating the siRNA molecule through electrostatic interactions, and then modifying hyaluronic acid through electrostatic interactions to form core-shell structured nanoparticles. This invention forms a complete technology chain from target validation, siRNA sequence design, nanodelivery system construction, in vivo and in vitro efficacy verification to the development of combination drug strategies. It also provides quantifiable efficacy evaluation biomarkers, offering a clear basis for clinical patient screening and efficacy monitoring.

Use of a quinazoline compound and a third-generation epidermal growth factor receptor (EGFR) inhibitor in a combined drug for treating non-small cell lung cancer. The quinazoline compound comprises at least one of a quinazoline derivative represented by formula (I), a salt thereof, a solvate thereof, a hydrate thereof, and a polymorph thereof.

The present application relates to a kind of cytidine choline dextrohydrotalcid derivatives and its preparation method and application, belong to biological medicine technical field.The present application is aimed at solving the technical problems of low blood-brain barrier penetration rate and limited treatment effect of existing edaravone dextrohydrotalcid compound preparation.The present application prepares a dextrohydrotalcid derivative (C-B) with boronic acid structure, then it is compounded with cytidine choline in specific pH buffer system, and forms cytidine choline dextrohydrotalcid derivative (C-D-B).The present application can effectively improve the efficiency of drug crossing blood-brain barrier by using the dynamic covalent characteristics of boronic ester bond and free radical responsiveness.The experimental results show that, compared with existing combination drug, the derivative of the present application can significantly reduce the infarction area of cerebral ischemia model animal, reduce cell damage and active oxygen level, and promote vascular regeneration, and show better treatment effect on ischemic brain injury.

The application discloses a kind of attenuated salmonella load adjuvant nano combination medicine, the combination medicine is modified to bacterial surface by means of amino and carboxyl condensation reaction, adamantane is simultaneously modified to adjuvant nano medicine surface using diselenium dynamic bond, then the host-guest interaction of adamantane and cyclodextrin is used to assemble two, and then nano medicine is stably combined on the surface of attenuated salmonella.Diselenium dynamic bond can be broken by ultrasound response, so as to realize the effect of drug release.This combination medicine has the tumor targeting enrichment ability of bacteria and the release characteristics of adjuvant nanoparticles under the action of ultrasonic wave, can realize targeted delivery and deep penetration in tumor tissue, and obtain significant tumor inhibition effect under ultrasonic stimulation.The experimental results show that the combination medicine exhibits good therapeutic effect in inhibiting tumor growth, and has excellent biological safety.

The present invention relates to combinations comprising a checkpoint inhibitor and a c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of the free base of Compound 1, as well as crystalline forms of salts of Compound 1, in combination with a checkpoint inhibitor. The invention further relates to methods of treating cancer by administering Compound 1 as a single agent or a combination described herein.

This invention belongs to the field of biomedical technology, specifically relating to triptolide liposomes (TP-lipo), their combined use, and their application in the prevention and treatment of tumors. To enhance the efficacy of triptolide in the treatment and prevention of tumors such as pancreatic cancer, cervical cancer, ovarian cancer, and colorectal cancer, and to improve its bioavailability and clinical application while reducing toxicity, this invention uses HSPC, DOPS, and cholesterol as liposome components to encapsulate triptolide monomers, thus preparing TP-lipo. Experiments have shown that TP-lipo exhibits anti-tumor activity: it directly kills tumor cells and reverses the immunosuppressive microenvironment, making it a potential drug for tumor treatment. TP-lipo, when used in combination with PD-1 antibodies, or in combination with radiotherapy, chemotherapy, or surgery, demonstrates a potent and synergistic anti-tumor effect with low toxicity. Therefore, the TP-lipo of this invention provides more clinical strategies for tumor treatment.

The application discloses a traditional Chinese medicine combined medicament for treating 2,4-dichlorophenoxyacetic acid-induced liver injury of livestock and poultry, which is prepared by compounding procyanidin B3, cryptotanshinone and resveratrol, and the three components have synergies and can effectively improve the 2,4-dichlorophenoxyacetic acid-induced liver injury problem of livestock and poultry. The application has simple formula and simple preparation process, can be developed into green and safe liver-protecting veterinary drugs and functional feed, and has good application and popularization value in the field of livestock and poultry breeding.

This invention relates to the field of biomedical technology, specifically to an antifungal nanoparticle, a combination drug, and its application. The antifungal nanoparticle is prepared by covalently linking the aptamer AU1 to drug-loaded silk fibroin nanoparticles via amide bonds. The mass ratio of the drug-loaded silk fibroin nanoparticles to the aptamer AU1 is 20:0.5~2.0. The antifungal nanoparticles of this invention are prepared by a desolvation method using voriconazole-loaded silk fibroin nanoparticles, and the targeting aptamer AU1 is attached to their surface using a carbodiimide chemical cross-linking method. This allows for specific recognition of Candida albicans, increasing drug accumulation at the infection site. Further combination with methylene blue-mediated photodynamic therapy can disrupt biofilm structures, enhance nanoparticle penetration, achieve synergistic bactericidal activity, and reduce systemic toxicity, providing a novel, highly effective, and low-toxicity treatment strategy for fungal biofilm infections.

The application provides a method for synchronously detecting multiple cell death modes in a tissue slice based on multiplex immunofluorescence, and belongs to the technical field of biological detection. The application realizes the synchronous labeling and visualization of multiple cell death modes in a single tissue slice, significantly improves the detection efficiency and saves precious samples; by integrating key biomarkers covering main cell death modes in the same detection system, a self-defined interpretation scheme based on multi-marker expression combination is constructed, effectively reducing the error caused by non-specific expression of a single marker, improving the reliability and rationality of the death mode classification, and providing a general solution for rapid screening of complex cell death networks. The application is suitable for anticancer drug efficacy evaluation, combination drug regimen screening and disease mechanism research, and has important scientific research value and clinical conversion prospect.

This invention discloses a combination drug of Akkermansia and an EET homologue and its uses, relating to the field of biomedical technology. Specifically, the combination drug of this invention comprises: A1) a first active ingredient, the first active ingredient comprising Akkermansia myxophilus; and A2) a second active ingredient, the second active ingredient comprising at least one of 14,15-epoxyeicosatetrienoic acid (14,15-EET) or an isomer of 14,15-epoxyeicosatetrienoic acid, a pharmaceutically acceptable salt, an ester, or a prodrug. The combination drug of this invention exhibits excellent anti-inflammatory and anti-tumor effects in LPS-induced inflammation models and LLC subcutaneous tumor models. The synergistic index SI > 1 calculated using the Bliss independent model indicates a good synergistic effect, and it can be used for the prevention, treatment, and prognostic improvement of non-small cell lung cancer.

The application discloses a drug interaction prediction and dose reference information generation method, system and device, and the method comprises the following steps: acquiring parameters of a Bruton's tyrosine kinase inhibitor as a target drug and an antiretroviral drug as an interaction drug; constructing and verifying a basic physiological pharmacokinetic model of each drug; integrating inhibition or induction parameters of the interaction drug on corresponding enzymes, constructing and verifying an interaction prediction model; running the verified model to simulate and calculate predicted exposure data of the target drug when the drugs are used in combination; and generating dose reference information meeting preset bioequivalence conditions by iteratively adjusting dose parameters of the target drug and re-simulating. The application realizes automatic, quantitative prediction and personalized dose scheme generation of specific drug combination interactions, and can provide key decision support for clinical combination drug use.

A combinational medicine of: esaxerenone or a pharmaceutically acceptable salt thereof; and a SGLT2 inhibitor.

This invention relates to the field of biomedicine, specifically to the combined application of interferon-alpha (IFN-α) and NF-κB signaling pathway inhibitors, particularly the application of interferon-alpha combined with bortezomib in the preparation of drugs for the prevention and / or treatment of viral infections. Host-produced lactate is a key microenvironmental factor driving the shift of IFN-α from "anti-inflammatory" to "pro-inflammatory." Lactic acid, in conjunction with IFN-α, excessively activates the NF-κB signaling pathway, thereby triggering a cytokine storm. Based on this novel mechanism, this invention creatively proposes the combined use of IFN-α and bortezomib. This combination effectively blocks lactate / IFN-α-induced NF-κB overactivation, retaining the potent antiviral activity of IFN-α while completely reversing its side effect of exacerbating inflammation in the later stages of viral infection, achieving a dual effect of "antiviral" and "inflammatory control."

The present application relates to a kind of combination drug composition for preventing or treating diffuse large B-cell lymphoma and its application, the active component of the combination drug composition is composed of first active component and second active component;The first active component is selected from selinexor or any one or at least two combinations of its pharmaceutically acceptable salt, isomer, solvate, metabolite;The second active component is selected from ritonavir or any one or at least two combinations of its pharmaceutically acceptable salt, isomer, solvate, metabolite.The combination drug composition has excellent treatment effect of diffuse large B-cell lymphoma, not only can reduce the dosage of selinexor, improve the safety of drug, but also has more significant inhibitory effect on diffuse large B-cell lymphoma than using single selinexor.

A method for screening antimicrobial combination drug compositions based on a conditional diffusion model and its application include the following steps: First, an experimental dataset is constructed containing single-drug and pairwise combination antimicrobial measurement data of antibiotics, metalloids, and antimicrobial peptides. Then, combining multimodal structure / sequence characterization and concentration-related phenotypic information, generative modeling and discriminative scoring are integrated to explore and screen the antimicrobial combination space. Candidate combinations are initially screened under Staphylococcus aureus Newman strain, and then further verified in methicillin-resistant Staphylococcus aureus to see if their antimicrobial advantage can be retained under drug-resistant conditions. This invention organically combines the LightGBM scorer with the conditional diffusion model generation mechanism to construct a closed-loop system of generation, evaluation, and screening. This not only improves the diversity and exploratory nature of combinations but also enhances screening efficiency and accuracy, providing high-quality candidate combinations for subsequent experimental verification.

The present application relates to the use of an antibody-drug conjugate, and a combined drug and the use thereof. Specifically provided are the use of an antibody-drug conjugate, a combined drug and the use thereof. The antibody-drug conjugate shows a significant pharmacodynamic effect of inhibiting tumor cell growth in various NSCLC cell lines with EGFR mutation expression and various human NSCLC PDX tumor models of AZD9291 drug resistance with EGFR mutation expression. In addition, the combined administration of the antibody-drug conjugate and an anti-PD-1 antibody or an anti-PD-L1 antibody shows a significant synergistic pharmacodynamic effect of inhibiting tumor cell growth in the human NSCLC PDX tumor model of AZD9291 drug resistance with EGFR mutation expression.

The present application relates to a kind of combination drug for treating kras mutant ovarian cancer and its application.The present application proves by experiment that RB7LP can inhibit the proliferation of ovarian cancer cells, further, can promote the senescence and apoptosis of part kras mutant ovarian cancer cells, simultaneously, it also proves that KRAS inhibitor or EGFR inhibitor can synergistically Palbociclib combined lethal KRAS mutant ovarian cancer, compared with the treatment effect of Palbociclib or sotoracib alone, it is superior, the combination drug of the present application can synergistically induce kras mutant ovarian cancer cell apoptosis, increase cancer cell inhibition rate, curative effect is good, with very strong clinical application value.

This invention discloses the use of a combination of nitroimidazole derivatives in the preparation of drugs for the prevention and treatment of drug-resistant tuberculosis, belonging to the field of biomedical technology. This invention fills the clinical research gap regarding the use of combination drugs of nitroimidazole derivatives in the prevention and treatment of drug-resistant tuberculosis, providing a method for its application in the preparation of drugs for this purpose. This invention demonstrates good therapeutic effects against drug-resistant tuberculosis by combining nitroimidazole derivatives with various other anti-tuberculosis drugs, and shows promise as a new drug for the prevention and treatment of drug-resistant tuberculosis.

A combination drug for treating kidney caner, said combination drug comprising a tyrosine kinase inhibitor combined with a dipeptidyl peptidase 4 inhibitor; and a therapeutic effect enhancer for a tyrosine kinase inhibitor, said therapeutic effect enhancer comprising a dipeptidyl peptidase 4 inhibitor and enhancing the therapeutic effect of the tyrosine kinase inhibitor on kidney cancer.

This invention relates to the field of drug safety assessment technology, and particularly to a drug safety assessment method and system based on multi-source data fusion. The method includes: receiving the SMILES structural formulas and research information of candidate drugs; encoding the SMILES structural formulas of the candidate drugs and each combination drug to obtain molecular structure feature vectors; constructing a knowledge graph by fusing multiple public biomedical databases to obtain knowledge graph embedding vectors; performing cross-modal multi-source information fusion on the molecular structure feature vectors and knowledge graph embedding vectors to obtain a multi-source fusion representation vector; inputting the concatenated vector into a prediction model to predict and calibrate drug-drug interactions and adverse reactions, obtaining calibration confidence levels; and conducting a safety assessment of drug interactions based on indications and calibration confidence levels, generating a comprehensive safety assessment report. This invention provides a reliable reference for decision-making regarding the safety of combination drug use during the drug development stage.

The present invention relates to a drug for treating or preventing ALK fusion gene-positive cancer positive for FGFR1 expression and positive for FGF2 expression at baseline, the drug comprising a compound having ALK inhibitory activity and a FGFR inhibitor in combination, a combination agent, a pharmaceutical composition, a preparation, a treatment or prevention method, or a drug for suppressing acquisition of resistance, a method for selecting a patient, and the like.

This invention belongs to the field of biomedicine, specifically relating to a combination drug composition for Ph+ALL and its application. This invention discloses a combination drug composition for Ph+ALL, characterized by comprising a BCL-2 inhibitor, a demethylating agent, and a TKI. The technical solution of this invention expands the chemotherapy-free treatment modality for Ph+ALL, not only enabling patients to achieve rapid and deep remission while observing no unacceptable treatment-related toxicities, but also significantly improving the quality of life of treatment-naïve patients, reducing treatment-related complications, decreasing the consumption of blood products, shortening hospital stays, and significantly reducing medical insurance expenditures.

This invention discloses the application of clozapine and its combination with chemotherapeutic drugs in the preparation of drugs for treating triple-negative breast cancer or breast cancer stem cells, belonging to the field of pharmaceutical technology. This invention experimentally verifies that clozapine can effectively inhibit the growth of breast cancer stem cells and has a strong growth-inhibiting effect on triple-negative breast cancer cell lines, but has no growth-inhibiting effect on other types of breast cancer cell lines and normal tissue cells, thus it can be used as a treatment drug for triple-negative breast cancer. Simultaneously, the combination of clozapine and chemotherapeutic drugs can significantly inhibit the growth of triple-negative breast cancer cells, and the inhibitory effect is significantly better than that of chemotherapeutic drugs alone. Clozapine alone and the combination of clozapine and chemotherapeutic drugs significantly inhibited the growth of triple-negative breast cancer tumors in mouse models, successfully solving the problem of drug resistance in triple-negative breast cancer caused by the inability of existing basic treatment drugs (chemotherapeutic drugs) to inhibit breast cancer stem cells.

The present invention relates to the use of a combination of two or more of a D2 agonist, an adenosine A2A receptor antagonist, a histamine H3 antagonist or inverse agonist, a mGluR5 receptor antagonist, or a nicotinic α4-β2 and / or α7 receptor agonist to increase D2 dopaminergic molecular signaling in the striatum for the treatment of psychiatric or neurological disorders in which anhedonia or motivation-related dysfunction exists (such as major depressive disorder, bipolar I or II disorder, post-traumatic stress disorder, addiction, anhedonia or motivation-related aspects of schizophrenia (e.g. negative symptoms) and Parkinson's disease (e.g. non-motor features such as depression and apathy)).

This invention relates to the pharmaceutical field, specifically to a combination drug of trifluoperazine and a PD-1 inhibitor and its uses. This invention, through the combined use of trifluoperazine and a PD-1 inhibitor in the treatment of oral squamous cell carcinoma, has achieved superior efficacy compared to monotherapy. The combination of trifluoperazine and a PD-1 inhibitor in this invention increases CD8... + T cell expression levels and CD3 + CD8 + CD25 + Regarding the proportion of T cell subsets, it has a synergistic effect, providing a new strategy for the treatment of oral squamous cell carcinoma and showing great application prospects.